Cite
Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278-2289doi: 10.1182/blood.2021012021.
Cutler, C., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., Mehta, R., Wang, T., Arora, M., Pusic, I., Saad, A., Shah, N. N., Abhyankar, S., Bachier, C., Galvin, J., Im, A., Langston, A., Liesveld, J., Juckett, M., Logan, A., Schachter, L., Alavi, A., Howard, D., Waksal, H. W., Ryan, J., Eiznhamer, D., Aggarwal, S. K., Ieyoub, J., Schueller, O., Green, L., Yang, Z., Krenz, H., Jagasia, M., Blazar, B. R., & Pavletic, S. (2021). Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood, 138(22), 2278-2289. https://doi.org/10.1182/blood.2021012021
Cutler, Corey, et al. "Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study." Blood vol. 138,22 (2021): 2278-2289. doi: https://doi.org/10.1182/blood.2021012021
Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 Dec 02;138(22):2278-2289. doi: 10.1182/blood.2021012021. PMID: 34265047; PMCID: PMC8641099.
Copy
Download .nbib